Author/Editor | Gradišnik, Suzana; Krajnc, Ivan | |
Title | Mehanizmi delovanja novih imunomodulirajočih zdravil za zdravljenje revmatoidnega artritisa | |
Translated title | Mechanisms of action of novel immunomodulating drugs in the management of rheumatoid arthritis | |
Type | članek | |
Source | In: Hojs R, Krajnc I, Pahor A, et al, editors. Zbornik predavanj in praktikum Iz prakse za prakso z mednarodno udeležbo. 13. srečanje internistov in zdravnikov splošne medicine; 2002 maj 10-11; Maribor. Maribor: Splošna bolnišnica Maribor, | |
Publication year | 2002 | |
Volume | str. 73-81 | |
Language | slo | |
Abstract | Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown aetiology. Agents that target cells and molecules involved in chronic inflammation are coming in use for the treatment of RA. Proliferation of autoimmune T lymphocytes can be arrested by leflunomide, an immunomodulating drug exerting its effects by inhibiting the mitochondrial enzyme dihydroorotate-dehydrogenase (DHODH), which plays a key role in the de novo ribonucleotide synthesis. Among the many cytokines involved in RA tumour necrosis factor alpha (TNF-alpha ) is believed to be crucial. Two agents for neutralizing TNF-alpha are available now: etanercept, a recombinant molecule, which is derived from a naturally occurring TNF-alpha antagonist, and infliximab, alpha chimeric monoclonal antibody against human TNF-alpha. | |
Descriptors | ARTHRITIS, RHEUMATOID ADJUVANTS, IMMUNOLOGIC TUMOR NECROSIS FACTOR RECEPTORS, INTERLEUKIN-2 RECEPTORS, ANTIGEN, T-CELL |